Blood purification therapy for severe sepsis: a multicenter, observational cohort study in northern Japan

Kasumi Satoh1,2, Kyoko Nomura2, Hajime Nakae1, Daisuke Kudo3,4, Shigeki Kushimoto3,4, Masatsugu Hasegawa5, Fumihito Ito6, Satoshi Yamanouchi7, Hiroyuki Honda8, Kohkichi Andoh7, Hajime Furukawa4, Yasuo Yamada9, Yuta Tsujimoto10 and Manabu Okuyama1,11

Abstract

Background: Sepsis is associated with life-threatening organ dysfunction caused by a dysregulated host response to infection. However, no specific therapy has been shown to improve mortality in patients with sepsis. We conducted a study to clarify the utilization status of various BPTs and the clinical characteristics of patients who received BPTs in northern Japan. In addition, the association of various BPTs with clinical outcomes was examined.

Methods: This is a sub-analysis of the Tohoku Sepsis Registry, a multicenter, prospective, observational cohort study. To determine whether BPT was independently associated with in-hospital mortality in patients with severe sepsis, the following analyses were performed. Differences between survivors and non-survivors were assessed using Wilcoxon rank sum tests for continuous variables and Chi-square tests for categorical variables. Univariate logistic regression analysis was used to evaluate the factors associated with in-hospital mortality. In the multivariate logistic regression analysis, adjustments were made for the variables that were significant in the univariate logistic regression analysis. Clinical factors associated with mortality were analyzed.

Results: We enrolled 616 consecutive patients (≥18 years) with median Sequential Organ Failure Assessment scores of 8.0. During median of 22 days hospitalization, 139 patients died (mortality 22.6%). 20.7% of patients with severe sepsis received any type of BPT (mortality 38.6%). BPT consisted of 65.1% continuous renal replacement therapy (CRRT) with renal indication (mortality 48.8%), 26.0% CRRT with non-renal indication (mortality 21.2%), 22.2% intermittent renal replacement therapy (mortality 32.1%), and 33.1% polymyxin B-immobilized fiber column-direct hemoperfusion (mortality 42.9%). Meanwhile, no BPT group (mortality 18.5%) showed a significantly lower mortality than any BPT group. Besides, in multivariate analyses, all BPT modes were not independently associated with all-cause mortality.

Conclusions: This study suggested the clinical status of BPTs for severe sepsis patients in northern Japan. Among all types of BPT, continuous renal replacement therapy (CRRT) for renal indication was most frequently selected. Severe sepsis patients received BPT had a higher mortality and severity; however, the BPT implementation may not be associated with mortality.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Sepsis is associated with life-threatening organ dysfunction caused by a dysregulated host response to infection [1]. In the USA, mortality rates have been reported to be >15% [2]. Radical treatments include the administration of antimicrobial agents and surgical source control. However, no specific therapy has been shown to improve mortality in patients with sepsis.

Acute kidney injury (AKI) is strongly associated with poor prognosis in patients with sepsis [3]. Renal replacement therapy is recommended for sepsis patients with AKI [4]. However, it is unclear whether renal replacement therapy improves survival or renal recovery after sepsis-induced AKI [5]. Along with renal replacement therapy, blood purification therapy (BPT) has been proposed as a treatment for modulating the inflammatory response in sepsis, even in patients without renal dysfunction [4, 5]. The in-hospital mortality rate in sepsis patients undergoing BPT is reported to be high, ranging from 41 to 79% in patients with renal and non-renal indications [6–9]. However, mortality rates are highly variable, and the number of reports is limited. There is little detailed information on the use of BPT modes in septic patients and mortality rates for each BPT mode.

Several studies have shown the potential of BPT in modulating the immune response. Two meta-analyses [10, 11] of small, randomized controlled trials evaluating the effects of hemoperfusion, plasma exchange, and hemofiltration with hemoperfusion demonstrated favorable results. However, the quality of these studies was not adequate. Even is the focus if only on renal replacement, the optimal timing and implementation remain unclear [12]. Thus, the benefits of BPT in terms of sepsis outcomes remain unclear. Mortality-related factors, such as age [13] and hepatic disease [14], have been reported in sepsis patients. However, there is no literature examining whether BPT is an independent clinical factor associated with survival.

We conducted a study based on prospective and continuously collected database to clarify the utilization status of various BPTs and the clinical characteristics of patients who received BPTs in northern Japan. In addition, the association of various BPTs with clinical outcomes was examined.

Methods

Study design

This is a sub-analysis of the Tohoku Sepsis Registry, a multicenter, prospective, observational cohort study conducted across 10 sites in the Tohoku district of northern Japan, including 3 university hospitals and 7 large community hospitals with >300 beds. The protocol of the Tohoku Sepsis Registry has been registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000010297). It is described in detail elsewhere [15]. The study design was approved by the Institutional Review Board of each institution and conforms to the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013). The need for informed consent was waived due to the observational nature of the study.

Study setting and participants

The Tohoku Sepsis Registry included consecutive patients admitted to intensive care units (ICUs) with severe sepsis or those presenting with severe sepsis after admission to ICUs or general wards in the 10 included hospitals between January and December 2015.

Participants were eligible if they were diagnosed with severe sepsis according to the 2012 International Sepsis Guidelines: sepsis-induced tissue hypoperfusion or organ dysfunction, including sepsis-induced hypotension, elevated serum lactate levels, low urine output despite adequate fluid resuscitation (<0.5 mL/kg/h for >2 h), acute lung injury with a ratio of arterial oxygen pressure (PaO2:FiO2) of <250.0 in the absence of pneumonia as the source of infection or a PaO2:FiO2 ratio of <200.0 in the presence of pneumonia as the source of infection, elevated serum creatinine levels (>2.0 mg/dL), elevated serum total bilirubin levels (>2.0 mg/dL), low platelet counts (<10.0×10^9/mm^3), and coagulopathy with an international normalized ratio of >1.5 [16]. Patients aged <18 years were excluded.

Data collection

The registered information includes that on age, sex, pre-existing comorbidities, and medications before admission, in addition to the unit where sepsis was diagnosed, the presence or absence of septic shock, severity as assessed using the Acute Physiologic Assessment and
Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores, and primary site of infection. Other information includes physiological data, testing results, and treatment details, including drugs, source control interventions, and BPTs. The lengths of ICU and hospital stay and outcomes at 28 days post-diagnosis and at discharge were documented.

AKI was diagnosed according to the AKI Network criteria [17], which are used for classifying the different stages of AKI (stages 0–3) based on serum creatinine levels and urine output. AKI stage 1 is defined as an elevated serum creatinine level of ≥0.3 mg/dL or an increase of 150.0–200.0% from the baseline serum creatinine level or a reduction in urine output of <0.5 mL/kg/h for >6 h. AKI stage 2 is defined as an increase of 200.0%–300.0% from the baseline serum creatinine level or a reduction in urine output of <0.5 mL/kg/h for >12 h. AKI stage 3 is defined as an elevated serum creatinine level of ≥4.0 mg/dL with an acute increase of ≥0.5 mg/dL or >300.0% from the baseline serum creatinine level or a reduction in urine output of <0.3 mL/kg/h for 24 h or anuria for 12 h.

BPT
In this study, BPT consisted of continuous renal replacement therapy (CRRT), including CRRT with renal and non-renal indications, intermittent renal replacement therapy (IRRT), and polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP). The indications for BPT were based on the clinical judgment of the attending physicians at each institution. The equipment used and operational settings were determined by the clinician based on resources available at the institution. No uniform protocol was followed.

Participants were divided into the no BPT and different BPT groups. Patients were included in the BPT group regardless of the frequency or duration of BPT. If multiple BPTs were administered, patients were classified into more than one BPT group.

Outcomes
The primary outcome of this study was in-hospital mortality. Secondary outcomes included 28-day mortality, ICU-free days, length of ICU stay, and length of hospital stay. In-hospital mortality and 28-day mortality were defined as all-cause mortality at discharge or 28 days after the diagnosis of sepsis, respectively. ICU-free days represented the number of days on which ICU admission was not required within a 28-day period following the diagnosis of severe sepsis. The number of ICU-free days for patients who died within the 28-day period was 0.

Statistical analysis
Baseline patient characteristics (age, sex, preexisting comorbidities, worst physiological data on day 1 of diagnosis, and treatment modalities) were compared between the two groups of BPT (BPT vs. no PBT) by using Wilcoxon rank sum tests for continuous variables and Chi-square tests for categorical variables. Continuous variables were tested for normality with the Shapiro–Wilk test, with all continuous variables showing the skewed distribution (p<0.05), thus summarized by median and interquartile range.

To determine whether BPT was independently associated with in-hospital mortality in patients with severe sepsis, the following analyses were performed. Differences between survivors and non-survivors were assessed using Wilcoxon rank sum tests for continuous variables and Chi-square tests for categorical variables. Univariate logistic regression analysis was used to evaluate the factors associated with in-hospital mortality at a significance level of 5%. Odds ratios and 95% confidence intervals were calculated. The results of univariate logistic regression analysis were used to select variables for multivariate logistic regression analysis. In the multivariate logistic regression analysis, adjustments were made for the type of BPT, as well as variables that were significant in the univariate logistic regression analysis. Since SOFA and APACHE II scores were correlated (Spearman’s rank correlation coefficient, r = 0.687; p < 0.001), only SOFA score was included in multivariable logistic regression analysis. SOFA score includes the Glasgow Coma Scale, mean arterial pressure, PaO2:FiO2 ratio, and platelet counts, which were also excluded from the multivariate logistic regression analysis. Eventually, type of BPT, SOFA score, lactate level, AKI stage, primary site of infection, mechanical ventilation use within 24 h, inotropes or vasopressors use were included in the multivariate logistic regression analysis. There were six BPT types included in multivariate logistic regression analysis: BPT, CRRT with renal indications, CRRT with non-renal indications, IRRT, and PMX-DHP. We performed six multivariate logistic regression models for each of the BPT types, and clinical factors associated with mortality were analyzed. The goodness of fit was assessed using the Hosmer–Lemeshow test. All statistical analyses were conducted using Stata® software, version 15.1 (StataCorp, College Station, Texas, USA). Significance was defined as a two-sided p value of <0.05.

Results
Patient characteristics
In total, 616 patients in the Tohoku Sepsis Registry were enrolled. The median (interquartile range [IQR]) age was 75.0 (65.0–83.0) years. The proportion of male patients was 61.5%. The median (IQR) APACHE II and SOFA scores were 20.0 (15.0–26.0) and 8.0 (5.0–11.0), respectively. Patient characteristics are shown in Table 1.
Table 1  Characteristics of the patients

| Variables                          | All (N = 616) | No BPT (N = 489) | Any BPT (N = 127) | p value |
|------------------------------------|---------------|------------------|-------------------|---------|
| Age (year)                         | 75 (65–83)    | 76 (66–84)       | 71 (63–81)        | 0.016   |
| Male sex                           | 379/616 (61.5)| 297/489 (60.7)   | 82/127 (64.6)     | 0.429   |
| **Severity**                       |               |                  |                   |         |
| APACHE II score (0–71)             | 20 (15–26)    | 19 (14–25)       | 25 (20–31)        | <0.001  |
| SOFA score (0–24)                  | 8 (5–11)      | 7 (5–10)         | 11 (8–14)         | <0.001  |
| **Comorbidity**                    |               |                  |                   |         |
| Chronic kidney disease             | 61/616 (9.9)  | 29/489 (5.9)     | 32/127 (25.2)     | <0.001  |
| Malignancy                         | 71/616 (11.5) | 49/489 (10.0)    | 22/127 (17.3)     | 0.022   |
| Diabetes mellitus                  | 176/616 (28.6)| 137/489 (28.0)   | 39/127 (30.7)     | 0.530   |
| Hepatic disease                    | 22/616 (3.6)  | 15/489 (3.1)     | 7/127 (5.5)       | 0.186   |
| Others                             | 229/616 (37.2)| 193/489 (39.5)   | 36/127 (28.3)     | 0.021   |
| **Physiological variable (Day 1)**|               |                  |                   |         |
| Worst GCS score                    | 14 (9–15)     | 14 (10–15)       | 13 (8–15)         | 0.034   |
| Worst heart rate (beats/min)       | 113 (95–128)  | 112 (96–127)     | 114 (92–130)      | 0.965   |
| Worst mean arterial pressure (mmHg)| 65.7 (53.7–82.5)| 67.3 (56.0–84.7) | 58.1 (46.0–72.7) | <0.001  |
| Lactate level (mg/dL)              | 25.2 (18.0–40.2)| 24.3 (18.0–36.9) | 34.2 (17.1–55.8) | 0.009   |
| PaO2/FiO2                           | 232.5 (133.3–328.1)| 236.8 (137.5–326.7)| 206.1 (127.8–328.1)| 0.390   |
| Worst creatinine level (mg/dL)     | 1.2 (0.8–2.2) | 1.1 (0.8–1.7)    | 2.9 (1.5–4.9)     | <0.001  |
| Bilirubin level (mg/dL)            | 0.9 (0.6–1.5) | 0.9 (0.6–1.5)    | 0.9 (0.5–1.5)     | 0.908   |
| Platelet count (cells × 104/mm³)   | 15.9 (10.2–23.1)| 16.8 (11.2–23.5) | 12.3 (7.3–19.0)   | <0.001  |
| **AKI-related variables (Day 1–3)**|               |                  |                   |         |
| AKI                                | 258/616 (41.9)| 152/489 (31.1)   | 106/127 (83.5)    | <0.001  |
| AKI stage                          |               |                  |                   | <0.001  |
| 0                                  | 358/616 (58.1)| 337/489 (69.0)   | 21/127 (16.5)     | –       |
| 1                                  | 63/616 (20.4) | 56/489 (11.5)    | 7/127 (5.5)       | –       |
| 2                                  | 57/616 (9.3)  | 53/489 (10.8)    | 4/127 (3.2)       | –       |
| 3                                  | 138/616 (22.4)| 43/489 (8.8)     | 95/127 (74.8)     | –       |
| **Primary site of infection**      |               |                  |                   | 0.006   |
| Lung                               | 217/616 (35.2)| 184/489 (37.6)   | 33/127 (26.0)     | –       |
| Urinary tract                      | 99/616 (16.0) | 82/489 (16.8)    | 17/127 (13.4)     | –       |
| Abdomen                            | 184/616 (29.8)| 143/489 (29.2)   | 41/127 (32.3)     | –       |
| Others                             | 116/616 (18.8)| 80/489 (16.4)    | 36/127 (28.4)     | –       |
| **Blood purification therapy**     |               |                  |                   |         |
| Any BPT                            | 127/614 (20.7)| –                 | 127/127 (100.0)   | –       |
| Any CRRT                           | 107/614 (17.4)| –                 | 107/127 (84.3)    | –       |
| CRRT for renal indications         | 82/613 (13.4) | –                 | 82/126 (65.1)     | –       |
| Within 24 h                        | 68/613 (11.1) | –                 | 68/126 (54.0)     | –       |
| Within 24 and 48 h                 | 7/613 (1.1)   | –                 | 7/126 (5.6)       | –       |
| After 48 h                         | 7/613 (1.1)   | –                 | 7/126 (5.6)       | –       |
| CRRT for non-renal indications     | 33/612 (5.4)  | –                 | 33/127 (26.0)     | –       |
| Within 24 h                        | 32/612 (5.2)  | –                 | 32/127 (25.2)     | –       |
| Within 24 and 48 h                 | 0/612 (0.0)   | –                 | 0/127 (0.0)       | –       |
| After 48 h                         | 1/612 (0.2)   | –                 | 1/127 (0.8)       | –       |
| IRRT                               | 28/611 (4.6)  | –                 | 28/126 (22.2)     | –       |
| Within 24 h                        | 8/611 (1.3)   | –                 | 8/126 (6.4)       | –       |
| Within 24 and 48 h                 | 4/611 (0.7)   | –                 | 4/126 (3.2)       | –       |
| After 48 h                         | 16/611 (2.6)  | –                 | 16/126 (12.7)     | –       |
| PMX-DHP                            | 42/611 (6.9)  | –                 | 42/127 (33.1)     | –       |
| Within 24 h                        | 37/611 (6.1)  | –                 | 37/127 (29.1)     | –       |
| Within 24 and 48 h                 | 4/611 (0.7)   | –                 | 4/127 (3.2)       | –       |
| After 48 h                         | 1/611 (0.2)   | –                 | 1/127 (0.8)       | –       |
| **Other therapies**                |               |                  |                   |         |
Detailed patient characteristics are provided in Table 5, according to the type of BPT. The proportions of patients treated with any BPT, any CRRT, IRRT, and PMX-DHP were 20.7%, 17.4%, 4.6%, and 6.9%, respectively.

Comparison of variables between the no BPT and any BPT groups showed the following results: the BPT group was a younger (median 76 [IQR 66–84] vs. 71 [63–81], p = 0.016) and a more severe disease group with higher APACHE II score (19 [14–25] vs. 25 [20–30], p < 0.001) and SOFA score (7 [5–10] vs. 11 [8–14], p < 0.001). Chronic kidney disease (5.9% vs. 25.2%, p < 0.001) and malignant disease (10.0% vs. 17.3%, p = 0.022) are more frequent comorbidities with BPT, and AKI (31.1% vs. 83.5%, p < 0.001) is more frequent as its complication. The proportion of patients receiving mechanical ventilation within 24 h (39.2% vs. 71.7%, p < 0.001), proportion of patients receiving inotropes or vasopressors (45.5% vs. 73.0%, p < 0.001) was higher in BPT group comparing with no BPT group.

Clinical outcomes according to the type of BPT
Table 2 reports the clinical outcomes according to the type of BPT. During a median hospitalization period of 22 days, a total of 139 patients died (mortality rate, 22.6%). The in-hospital mortality rates in patients treated with no BPT, any BPT, any CRRT, CRRT for renal indications, CRRT for non-renal indications, IRRT, and PMX-DHP were 18.5%, 38.6%, 41.1%, 48.8%, 21.2%, 32.1%, and 42.9%, respectively. Significant differences in in-hospital mortality rates were observed between patients treated with any BPT (p < 0.001), any CRRT (p < 0.001), CRRT for renal indications (p < 0.001), or PMX-DHP (p < 0.001) and those treated with no BPT. The number of ICU-free days differed significantly between the no BPT and any BPT groups (22.0 vs. 12.0 days). According to the type of BPT, only the IRRT group exhibited no significant difference in the number of ICU-free days. Patients in the other BPT groups had significantly fewer ICU-free days than those in the no BPT group. The number of ICU days was significantly higher in BPT groups other than the PMX-DHP group than in the no BPT group. The number of hospital days was also significantly higher in the any BPT, CRRT for non-renal indications, and IRRT groups than in the no BPT group.

Factors associated with in-hospital mortality
Significant differences in the following variables were observed between survivors and non-survivors: APACHE II (p < 0.001), SOFA (p < 0.001), and Glasgow Coma Scale (p < 0.001) scores, heart rate (p = 0.030), mean arterial pressure (p < 0.001), serum lactate levels (p < 0.001), PaO2:FiO2 ratio (p < 0.001), serum creatinine levels (p < 0.001), platelet counts (p = 0.020), AKI (p < 0.001), AKI stage (p < 0.001), and primary site of infection (p < 0.001), mechanical ventilation use (within 24 h of diagnosis) (p < 0.001), use of inotropes or vasopressors (p < 0.001), any BPT (p < 0.001), any CRRT (p < 0.001), CRRT for renal indications (p < 0.001), and PMX-DHP (p = 0.005). In the univariate logistic regression analysis, the same variables were significantly associated with mortality at discharge, except for serum creatinine levels (Table 3).

Effects of BPT type on mortality
In the multivariate logistic regression analysis of BPT type, all BPT types were not associated with in-hospital mortality. Instead, SOFA score, serum lactate levels, and AKI stage 3 were significantly associated with in-hospital mortality (Table 4).

Discussion
Based on the prospective and continuously collected database of severe sepsis patients recruited from the Tohoku Sepsis Registry in northern Japan, 20.7% of patients with severe sepsis received any type of BPT. The in-hospital mortality rate for patients who received any BPT was...
Table 2  Differences in clinical outcomes between those treated with BPT and without BPT

|                          | Mortality at discharge | Mortality at 28 days | 28-day ICU-free days | ICU days | Hospital days |
|--------------------------|------------------------|----------------------|----------------------|----------|---------------|
|                          | N                      | p-value              | N                    | p-value  | Median        | p-value  | Median   | p-value   |
| All (N=616)              |                        |                      |                      |          |               |          |          |           |
|                          | 139/616 (22.6)         | –                    | 110/499 (22.0)       | –        | 20.5 (5.0–25.0) | –        | 6.0 (3.0–11.5) | –        |
| No BPT (N = 489)         | 90/487 (18.5) REF       | REF                  | 69/378 (22.0) REF    | REF      | 22.0 (11.0–22.0) REF | 5.0 (3.0–11.0) REF |
| Any BPT (N=127)          | 49/127 (38.6) <0.001   | 41/119 (34.5) <0.001 | 12.0 (0.0–21.0) <0.001 | 8.0 (4.0–16.0) <0.001 | 28.0 (13.0–69.0) 0.037 |
| Any CRRT (N=107)         | 44/107 (41.1) <0.001   | 37/99 (37.4) <0.001  | 9.0 (0.0–20.0) <0.001 | 8.0 (4.0–17.0) <0.001 | 27.0 (12.0–69.0) 0.090 |
| CRRT for renal indications (N=82) | 40/82 (48.8) <0.001 | 33/78 (42.3) <0.001 | 30 (0.0–19.0) 0.003 | 8.0 (4.0–18.0) 0.001 | 26.5 (9.0–72.0) 0.016 |
| CRRT for non-renal indications (N=33) | 7/33 (21.2) 0.833 | 6/29 (20.7) 0.744 | 17.0 (1.0–21.0) <0.001 | 9.0 (6.0–15.0) 0.003 | 34.0 (22.0–69.0) 0.011 |
| IRRT (N=28)              | 9/28 (32.1) 0.074      | 5/27 (18.5) 0.973    | 19.0 (7.5–23.0) 0.061 | 8.0 (4.5–14.0) 0.031 | 45.5 (26.0–70.5) 0.004 |
| PMX-DHP (N=42)           | 18/42 (42.9) <0.001    | 16/40 (40.0) 0.001   | 10.0 (0.0–21.0) <0.001 | 7.5 (3.0–17.0) 0.117 | 33.0 (14.0–64.0) 0.089 |

Data are expressed as medians (interquartile ranges) for continuous variables and numbers (%) for categorical variables.

Missing data were not included. The Wilcoxon rank sum test was used for the continuous variables, and the Chi-square test was used for categorical variables.

BPT: blood purification therapy, CRRT: continuous renal replacement therapy, IRRT: intermittent renal replacement therapy, PMX-DHP: polymyxin B immobilized fiber column-direct hemoperfusion, ICU: intensive care unit, REF: reference.
Table 3 The differences between survivors and non-survivors

| Variables                                      | Survivors (N = 477) | Non-survivors (N = 139) | p      | Unadjusted OR (95% CI) |
|------------------------------------------------|---------------------|-------------------------|--------|------------------------|
| Age (year)                                     | 76 (65–83)          | 75 (65–84)              | 0.808  | 1.001 (0.988–1.014)    |
| Male sex                                       | 285/477 (67.6)      | 94/139 (59.7)           | 0.093  | 0.711 (0.477–1.060)    |
| **Severity**                                   |                     |                         |        |                        |
| APACHE II score (0–71)                         | 19 (14–24)          | 26 (22–33)              | <0.001 | 1.112 (1.082–1.142)    |
| SOFA score (0–24)                              | 7 (5–10)            | 10 (7–13)               | <0.001 | 1.215 (1.152–1.282)    |
| **Comorbidity**                                |                     |                         |        |                        |
| Chronic kidney disease                         | 42/477 (8.8)        | 19/139 (13.7)           | 0.091  | 1.640 (0.920–2.924)    |
| Malignancy                                     | 50/477 (10.5)       | 21/139 (15.1)           | 0.133  | 1.520 (0.877–2.631)    |
| Diabetes mellitus                              | 143/477 (30.0)      | 33/139 (23.7)           | 0.152  | 0.727 (0.467–1.126)    |
| Hepatic disease                                | 17/477 (3.6)        | 5/139 (3.6)             | 0.985  | 0.985 (0.366–2.787)    |
| Others                                         | 180/477 (37.7)      | 49/139 (33.3)           | 0.594  | 0.903 (0.612–1.333)    |
| **Physiological variables (day 1)**            |                     |                         |        |                        |
| Worst GCS score                                | 14 (10–15)          | 11 (6–14)               | <0.001 | 0.863 (0.824–0.905)    |
| Worst heart rate (beats/min)                   | 111 (95–126)        | 119 (102–131)           | 0.030  | 1.006 (0.998–1.014)    |
| Worst mean arterial pressure (mmHg)            | 66.7 (56.0–86.0)    | 59.3 (46.7–73.7)        | <0.001 | 0.979 (0.969–0.989)    |
| Lactate level (mg/dL)                          | 243 (17.1–37.8)     | 30.6 (18.8–62.3)        | <0.001 | 1.015 (1.009–1.021)    |
| PaO2/FIO2                                      | 243.5 (148.4–333.3) | 180.6 (94.6–312.5)      | <0.001 | 0.997 (0.996–0.999)    |
| Worst creatinine level (mg/dL)                  | 1.2 (0.8–2.0)       | 1.6 (1.0–2.9)           | <0.001 | 1.083 (0.983–1.194)    |
| Bilirubin level (mg/dL)                        | 0.9 (0.6–1.5)       | 1.0 (0.6–1.5)           | 0.379  | 1.055 (0.983–1.194)    |
| Platelet count (cells x 10^4/mm^3)             | 164 (10.8–23.4)     | 14.2 (7.9–22.4)         | 0.020  | 0.981 (0.962–1.000)    |
| **AKI-related variables (day 1–3)**            |                     |                         |        |                        |
| AKI                                            | 167/477 (35.0)      | 91/139 (65.5)           | <0.001 | 3.519 (2.366–5.235)    |
| AKI stage                                      |                     |                         |        |                        |
| 0                                              | 310/477 (65.0)      | 48/139 (34.5)           | <0.001 | 1.000                  |
| 1                                              | 48/477 (10.1)       | 15/139 (10.8)           | 2.018  | 1.049–3.884            |
| 2                                              | 41/477 (8.6)        | 16/139 (11.5)           | 2.520  | 1.312–4.842            |
| 3                                              | 78/477 (16.4)       | 60/139 (43.2)           | 4.968  | 3.157–7.819            |
| Primary site of infection                      |                     |                         | <0.001 |                       |
| Lung                                           | 147/477 (30.8)      | 70/139 (50.4)           |         | 1.000                  |
| Urinary tract                                  | 155/477 (32.5)      | 29/139 (20.9)           | 0.210  | 0.100–0.441            |
| Abdomen                                        | 90/477 (18.9)       | 9/139 (6.5)             | 0.393  | 0.241–0.640            |
| Others                                         | 84/477 (17.8)       | 31/139 (22.3)           | 0.766  | 0.464–1.263            |
| **Blood purification therapy**                 |                     |                         |        |                        |
| Any BPT                                        | 72/475 (15.2)       | 38/139 (34.5)           | <0.001 | 2.952 (1.920–4.540)    |
| Any CRRT                                       | 63/475 (13.3)       | 44/139 (31.7)           | <0.001 | 3.029 (1.941–4.727)    |
| CRRT for renal indications                     | 42/474 (8.9)        | 40/139 (28.8)           | <0.001 | 4.156 (2.559–6.750)    |
| CRRT for non-renal indications                 | 26/473 (5.5)        | 7/139 (5.0)             | 0.833  | 0.912 (0.387–2.148)    |
| IRRT                                           | 19/474 (4.0)        | 9/137 (6.6)             | 0.207  | 1.684 (0.744–3.812)    |
| PMX-DHP                                        | 24/473 (5.1)        | 18/138 (13.0)           | 0.005  | 2.806 (1.475–5.340)    |
| **Other therapies**                            |                     |                         |        |                        |
| Mechanical ventilation within 24 h             | 190/474 (40.1)      | 91/138 (65.9)           | <0.001 | 2.894 (1.946–4.305)    |
| Inotropes or vasopressors                      | 218/472 (46.2)      | 94/138 (68.1)           | <0.001 | 2.489 (1.667–3.718)    |
| Antimicrobial therapy                          | 458/462 (99.1)      | 132/134 (98.5)          | 0.522  | 0.576 (0.104–3.182)    |
| Drainage or operation                          | 178/474 (29.1)      | 43/138 (31.2)           | 0.169  | 1.329 (0.886–1.993)    |

Data are expressed as medians (interquartile ranges) for continuous variables and numbers (%) for categorical variables
The Wilcoxon rank sum test was used for the continuous variables, and the Chi-square test was used for categorical variables
Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were analyzed using a univariable logistic regression model

**APACHE II** Acute Physiology and Chronic Health Evaluation II, **SOFA** Sequential Organ Failure Assessment, **GCS** Glasgow Coma Scale, **AKI** acute kidney injury, **BPT** blood purification therapy, **CRRT** continuous renal replacement therapy, **IRRT** intermittent renal replacement therapy, **PMX-DHP** polymyxin B immobilized fiber column-direct hemoperfusion
Table 4 Factors influencing in-hospital mortality in multivariable logistic regression analysis

|                          | Any BPT (N = 127) | Any CRRT (N = 107) | CRRT for renal indications (N = 82) | CRRT for non-renal indications (N = 33) | IRRT (N = 28) | PMX-DHP (N = 42) |
|--------------------------|-------------------|--------------------|-------------------------------------|------------------------------------------|--------------|-----------------|
|                          | OR 95% CI         | OR 95% CI          | OR 95% CI                           | OR 95% CI                                | OR 95% CI    | OR 95% CI       |
| Odds ratio               | 1.161 (0.613–2.200) | 1.259 (0.642–2.465) | 1.579 (0.711–3.506)                  | 0.787 (0.299–2.072)                       | 0.806 (0.551–1.179) | 1.491 (0.794–2.798) |
| SOFA score               | 1.137 (1.051–1.230) | 1.137 (1.051–1.230) | 1.139 (1.052–1.232)                  | 1.135 (1.049–1.229)                       | 1.126 (1.040–1.219) | 1.134 (1.048–1.227) |
| Lactate level            | 1.010 (1.003–1.018) | 1.010 (1.003–1.018) | 1.011 (1.003–1.018)                  | 1.011 (1.003–1.018)                       | 1.011 (1.003–1.018) | 1.009 (1.002–1.017) |
| AKI stage (Day 1–3)      |                   |                    |                                     |                                          |              |                 |
| 0                        | 1.000 –           | 1.000 –            | 1.000 –                             | 1.000 –                                  | 1.000 –      | 1.000 –         |
| 1                        | 0.902 (0.404–2.011) | 0.898 (0.402–2.006) | 0.905 (0.406–2.019)                  | 0.895 (0.401–1.200)                       | 0.881 (0.394–1.966) | 0.925 (0.414–2.066) |
| 2                        | 1.679 (0.783–3.598) | 1.690 (0.789–3.620) | 1.664 (0.777–3.563)                  | 1.631 (0.759–3.502)                       | 1.671 (0.778–3.587) | 1.736 (0.808–3.730) |
| 3                        | 2.427 (1.260–4.674) | 2.337 (1.211–4.507) | 1.997 (0.956–4.169)                  | 2.650 (1.517–4.632)                       | 2.799 (1.562–5.011) | 2.575 (1.469–4.513) |
| Primary site of infection|                   |                    |                                     |                                          |              |                 |
| Lung                     |                   |                    |                                     |                                          |              |                 |
| Urinary tract            | 0.181 (0.075–0.439) | 0.184 (0.076–0.442) | 0.187 (0.078–0.450)                  | 0.186 (0.077–0.450)                       | 0.173 (0.069–0.430) | 0.175 (0.072–0.424) |
| Abdomen                  | 0.384 (0.209–0.705) | 0.379 (0.205–0.698) | 0.376 (0.204–0.694)                  | 0.399 (0.218–0.731)                       | 0.366 (0.199–0.674) | 0.364 (0.197–0.673) |
| Others                   | 0.674 (0.372–1.222) | 0.668 (0.368–1.212) | 0.662 (0.365–1.201)                  | 0.682 (0.378–1.231)                       | 0.693 (0.384–1.249) | 0.660 (0.365–1.195) |
| Mechanical ventilation within 24 h | 0.974 (0.559–1.699) | 0.975 (0.368–1.212) | 0.988 (0.567–1.722)                  | 1.015 (0.581–1.771)                       | 1.024 (0.586–1.789) | 0.972 (0.558–1.693) |
| Inotropes or vasopressors | 1.360 (0.746–2.479) | 1.343 (0.737–2.449) | 1.298 (0.709–2.378)                  | 1.388 (0.760–2.536)                       | 1.441 (0.786–2.640) | 1.367 (0.749–2.494) |

ORs (95% CI) were estimated using multivariate analysis adjusted for significant covariates in the univariable analysis.

Due to collinearity with the APACHE II score, the SOFA score was used for all analyses.

Variables used for calculating the SOFA score, i.e., GCS score, MAP, PaO₂/FiO₂ ratio, and platelet count, were not included in the multivariable model.

For all multivariable logistic regression models, the p-values for the Hosmer–Lemeshow test were between 0.165 and 0.254.

BPT blood purification therapy, CRRT continuous renal replacement therapy, IRRT intermittent renal replacement therapy, PMX-DHP polymyxin B immobilized fiber column-direct hemoperfusion, OR odds ratio, CI confidence interval, AKI acute kidney injury.
Among all types of BPT, CRRT for renal indication was most frequently selected. BPT consisted of 65.1% CRRT with renal indication (mortality 48.8%), 26.0% CRRT with non-renal indication (mortality 21.2%), and 22.2% IRRT (mortality 32.1%), and 33.1% PMX-DHP (mortality 42.9%). Meanwhile, no BPT group (mortality 18.5%) showed a significantly lower mortality than any BPT group. According to BPT type, the CRRT for non-renal indications group and IRRT group exhibited relatively low mortality rates. Besides, any BPT was not independently associated with all-cause in-hospital mortality. To our knowledge, this is the first study based on prospective cohort focusing on the effectiveness of BPTs for severe sepsis.

Compared to previous Japanese study [18] that aggregated BPT patients in critical care, our PMX-DHP utilization rate is comparatively lower (33.1% vs. 43.4%) and our CRRT utilization rate is apparently higher (84.3% vs. 46.3%). While that previous study did its patient collection in 2013, ours in 2015. At international society of intensive care and emergency medicine conference in 2014, a randomized controlled trial reported did not confirm mortality benefit of PMX-DHP in patients with septic shock due to peritonitis [19], which was published early in 2015 [20]. This turn of the tide against PMX-DHP may have affected the results. The cohort in the previous Japanese study was sepsis patients, but severe sepsis was selected in this study; thus, CRRT may be selected more frequently for unstable hemodynamics.

In previous studies, the 28-day and in-hospital mortality rates of sepsis patients treated with BPTs ranged from 21 to 67% [6, 8, 9, 20–27] and 41% to 79% [6–9], respectively, and the lengths of ICU and hospital stay ranged from 7 to 26 days [6, 9, 20, 24, 26, 27] and 23 days to 59 days [6, 9, 21, 24], respectively. In this study, the 28-day and in-hospital mortality rates were 34.5% and 38.6%, respectively. This 28-day mortality rate is comparable to those in previous studies [6, 8, 9, 20–27]. The in-hospital mortality rate is lower than those in previous studies [6–9], although the severity of illness in the patients in this study receiving BPT was not particularly low in terms of APACHE II and SOFA scores. The lengths of ICU and hospital stay were shorter in our study but were broadly comparable to those reported elsewhere [6, 9, 20, 21, 24, 26, 27].

The mortality rates at 28 days and at discharge were significantly higher in the any BPT group than in the no BPT group (34.5% vs. 18.3% and 38.6% vs. 18.5%, respectively). We consider that this result may have been influenced by the high severity of illness in patients requiring BPT. On analysis according to BPT type, similarly high mortality rates were observed in the CRRT for renal indications and PMX-DHP groups. In contrast, the CRRT for non-renal indications group may have exhibited relatively low mortality rates and differed from other modalities in terms of other characteristics (e.g., low APACHE II scores and less renal impairment). The IRRT group also did not exhibit a significantly higher mortality rate. The IRRT group was also the only group to not exhibit significant differences in the number of ICU-free days. From this group, 50.0% of patients were also included in the CRRT for renal indications group, and in 57.1% of patients, treatment commenced > 48 h after diagnosis. It is possible that IRRT may have been administered to a patient population with stable circulatory hemodynamics. This may have been responsible for the lack of significance in mortality rates and the number of ICU-free days in the IRRT group compared with those in the no BPT group.

Our findings also suggested that none of the BPTs was independently associated with all-cause in-hospital mortality. Although the BPT groups tended to have higher mortality rates, there was no evidence to suggest that BPTs contributed to adverse effects on the outcomes of this study. There is no clear evidence that a particular BPT (CRRT for renal indications [6, 7, 23, 24, 26], CRRT for non-renal indications [8], or PMX-DHP [21]) is associated with better clinical outcomes, and our data support this. It may be difficult to expect significant improvements in prognosis with current BPTs. The establishment of a new method of BPT is eagerly awaited. Novel methods, including methods using the AN69 surface-treated hemofilter (sepXiris®) [28], modified AN69 surface-treated hemofilter (oXiris®) [29, 30], and extracorporeal cytokine adsorption device (CytoSorb®) [31], are currently being investigated. Further, large-scale studies are needed to evaluate the prognosis associated with the use of these methods.

This study has several limitations. First, the protocols of the various types of BPTs were based on the clinical judgment of the attending physicians at each institution and were not standardized. Thus, there was potential for variability in the application of BPT (e.g., indication, blood flow rate, dialysate flow rate, replacement flow rate, ultrafiltration rate, type of anticoagulation, and type of membrane). To address this, we included the institution as a variable in the multivariate logistic regression analysis. Second, this study did not have an adequately large sample size and may not be well adjusted for confounding variables. These limitations may affect the external validity of this study. Therefore, these findings should be interpreted with caution.

**Conclusions**

Our study showed that 20.7% of patients with severe sepsis received any BPT, and the mortality rate of patients who received any BPT was 38.6%. Among all types of BPT, CRRT for renal indication was most frequently selected. Patients who received BPT showed higher...
severity of illness, and the mortality of any BPT group was significantly higher than that of no BPT group. According to BPT type, the CRRT for non-renal indications group and IRRT group may have exhibited relatively low mortality rates. BPT may not be independently associated with all-cause in-hospital mortality, although patients with severe sepsis who were treated with BPTs exhibited higher mortality rates. More detailed analyses adjusting for potential confounding variables are needed in additional cohorts in the future.

Appendix
See Table 5.

| Variables                              | All (N = 616) | No BPT (N = 489) | Any BPT (N = 127) | Any CRRT (N = 107) | CRRT for renal indications (N = 82) | CRRT for non-renal indication (N = 33) | IRRT (N = 28) | PMX-DHP (N = 42) |
|----------------------------------------|---------------|------------------|-------------------|--------------------|-------------------------------------|----------------------------------------|---------------|-----------------|
| Age (year)                             | 75.0 (65.0–83.0) | 76.0 (66.0–84.0) | 71.0 (63.0–81.0) | 71.0 (61.0–82.0) | 71.0 (61.0–80.0) | 73.0 (60.0–84.0) | 71.0 (60.0–78.5) | 72.5 (62.0–79.0) |
| Male sex                               | 379/616 (61.5) | 297/489 (60.7)   | 82/127 (64.6)     | 69/107 (64.5)     | 54/82 (65.9) | 12/33 (36.4) | 24/28 (85.7) | 25/42 (59.5)   |
| Severity                               |               |                  |                   |                    |                      |                          |               |                 |
| APACHE II score (0–71)                 | 20.0 (15.0–26.0) | 19.0 (14.0–25.0) | 25.0 (20.0–31.0) | 25.0 (19.0–32.0) | 25.0 (20.0–32.5) | 21.0 (17.0–29.0) | 26.0 (22.0–29.0) | 26.0 (21.0–29.0) |
| SOFA score (0–24)                      | 8.0 (5.0–11.0) | 7.0 (5.0–10.0)   | 11.0 (8.0–14.0)   | 11.0 (8.0–14.0)   | 11.0 (8.0–14.0) | 10.0 (9.0–11.0) | 9.0 (8.0–12.0) | 11.0 (9.0–14.0) |
| Comorbidity                            |               |                  |                   |                    |                      |                          |               |                 |
| Chronic kidney disease                 | 61/616 (9.9) | 29/489 (5.9)     | 32/127 (25.2)     | 25/107 (23.4)     | 23/82 (28.1) | 3/33 (9.1) | 16/28 (57.1) | 4/42 (9.5)     |
| Malignancy                             | 71/616 (11.5) | 49/489 (10.0)    | 22/127 (17.3)     | 19/107 (17.8)     | 16/82 (19.5) | 3/33 (9.1) | 2/28 (7.1) | 11/42 (26.2)   |
| Diabetes mellitus                      | 176/616 (28.6) | 137/489 (28.0)  | 39/127 (30.7)     | 33/107 (30.8)     | 25/82 (30.5) | 10/33 (30.3) | 12/28 (42.9) | 7/42 (16.7)    |
| Hepatic disease                        | 22/616 (3.6) | 15/489 (3.1)     | 7/127 (5.5)       | 6/107 (5.6)       | 5/82 (6.1) | 1/33 (3.0) | 1/28 (3.6) | 2/42 (4.8)     |
| Stroke                                 | 89/616 (14.5) | 82/489 (16.8)    | 7/127 (5.5)       | 7/107 (6.5)       | 6/82 (7.3) | 2/33 (6.1) | 1/28 (3.6) | 2/42 (4.8)     |
| Heart failure (acute and/or chronic)   | 64/616 (10.4) | 44/489 (9.0)     | 20/127 (15.8)     | 18/107 (16.8)     | 14/82 (17.1) | 4/33 (12.1) | 6/28 (21.4) | 4/42 (9.5)     |
| Collagen disease                       | 32/616 (5.2) | 26/489 (5.3)     | 6/127 (4.7)       | 5/107 (4.7)       | 4/82 (4.9) | 2/33 (6.1) | 0/28 (0.0) | 1/42 (2.4)     |
| Myocardial infarction (acute and/or old) | 27/616 (4.4) | 21/489 (4.3)    | 6/127 (4.7)       | 6/107 (5.6)       | 4/82 (4.9) | 3/33 (9.1) | 0/28 (0.0) | 1/42 (2.4)     |
| Gastroduodenal ulcer                   | 27/616 (4.4) | 22/489 (4.5)     | 5/127 (3.9)       | 0/107 (0.0)       | 2/82 (2.4) | 2/33 (6.1) | 3/28 (10.7) | 1/42 (2.4)     |
| Arterial disease                       | 25/616 (4.1) | 22/489 (4.5)     | 3/127 (2.4)       | 2/107 (1.9)       | 2/82 (2.4) | 0/33 (0.0) | 0/28 (0.0) | 1/42 (2.4)     |
| Chronic Obstructive Pulmonary Disease  | 22/616 (3.6) | 21/489 (4.3)     | 1/127 (0.8)       | 1/107 (0.9)       | 1/82 (1.2) | 1/33 (3.0) | 1/28 (3.6) | 1/42 (2.4)     |
| Physiological variable (Day 1)         |               |                  |                   |                    |                      |                          |               |                 |
| Worst GCS score                        | 14.0 (9.0–15.0) | 14.0 (10.0–15.0) | 13.0 (8.0–15.0) | 13.5 (8.0–15.0) | 13.5 (8.0–15.0) | 14.0 (6.0–14.0) | 14.0 (10.0–15.0) | 13.0 (8.0–14.0) |
| Worst heart rate (beats/ min)           | 113.0 (95.0–128.0) | 112.0 (96.0–127.0) | 114.0 (92.0–130.0) | 114.0 (92.0–130.0) | 115.0 (95.0–135.0) | 113.0 (89.0–120.0) | 109.0 (79.5–130.0) | 123.5 (98.0–141.0) |
| Worst mean arterial pressure (mmHg)     | 65.7 (53.7–82.5) | 67.3 (56.0–84.7) | 58.3 (46.0–72.7) | 58.0 (45.0–68.7) | 57.3 (43.0–68.3) | 62.0 (49.3–73.3) | 61.5 (51.3–77.5) | 52.8 (41.3–64.0) |
| Variables | All (N = 616) | No BPT (N = 489) | Any BPT (N = 127) | Any CRRT (N = 107) | CRRT for renal indications (N = 82) | CRRT for non-renal indication (N = 33) | IRRT (N = 28) | PMX-DHP (N = 42) |
|-----------|---------------|-----------------|-----------------|-----------------|----------------|----------------|---------------|----------------|
| Lactate level (mg/dL) | 25.2 (18.0–40.2) | 24.3 (18.0–36.9) | 34.2 (17.1–55.8) | 34.2 (18.9–55.9) | 34.2 (18.0–54.6) | 38.0 (29.7–71.1) | 36.0 (49.1–78.6) | 38.0 (27.0–64.0) |
| PaO2/FiO2 | 232.5 (133.3–328.1) | 236.8 (137.5–326.7) | 206.1 (127.8–312.8) | 230.1 (127.8–332.9) | 198.5 (113.8–313.0) | 262.4 (137.5–373.5) | 112.4 (96.3–309.5) | 186.8 (117.5–308.2) |
| Worst creatinine level (mg/dL) | 1.2 (0.8–2.2) | 1.1 (0.8–1.7) | 2.9 (1.5–4.9) | 2.7 (1.5–4.4) | 3.1 (1.7–4.9) | 1.7 (1.0–2.5) | 2.3 (1.4–3.2) | 2.2 (1.4–3.6) |
| Bilirubin level (mg/dL) | 0.9 (0.6–1.5) | 0.9 (0.6–1.5) | 0.9 (0.5–1.5) | 0.9 (0.5–1.5) | 0.9 (0.5–1.5) | 0.8 (0.6–1.3) | 2.3 (2.0–2.6) | 1.3 (1.4–3.6) |
| Platelet count (cells x 10^9/ mm^3) | 15.9 (10.2–23.1) | 16.8 (11.2–23.5) | 12.3 (7.3–19.0) | 12.3 (7.2–19.0) | 11.3 (6.8–18.2) | 13.5 (9.6–27.7) | 15.4 (9.1–21.5) | 9.3 (5.5–18.2) |

**AKI-related variables (Day 1–3)**

| AKI stage | 0 | 1 | 2 | 3 |
|-----------|----------------|----------------|----------------|----------------|
| 0 | 358/616 (58.1) | 337/489 (69.0) | 21/127 (16.5) | 14/107 (13.1) |
| 1 | 63/616 (20.4) | 56/489 (11.5) | 7/127 (5.5) | 6/107 (5.6) |
| 2 | 57/616 (9.3) | 53/489 (10.8) | 4/127 (3.2) | 2/107 (1.9) |
| 3 | 138/616 (22.4) | 43/489 (8.8) | 95/127 (74.8) | 85/107 (79.4) |

**Primary site of infection**

| Lung | 217/616 (35.2) | 184/489 (37.6) | 33/127 (26.0) | 26/107 (24.3) |
| Urinary tract | 99/616 (16.0) | 82/489 (16.8) | 17/127 (13.4) | 12/107 (11.2) |
| Abdomen | 184/616 (29.8) | 143/489 (29.2) | 41/127 (32.3) | 37/107 (34.6) |
| Central nerve system | 8/616 (1.3) | 7/489 (1.4) | 1/127 (0.8) | 1/107 (0.9) |
| Soft tissue | 44/616 (7.1) | 30/489 (6.1) | 14/127 (11.0) | 11/107 (10.3) |
| Skeletal system | 5/616 (0.8) | 5/489 (1.0) | 0/127 (0.0) | 0/107 (0.0) |
| Wound | 5/616 (0.8) | 5/489 (1.0) | 0/127 (0.0) | 0/107 (0.0) |
| Intravascular catheter | 11/616 (1.8) | 5/489 (1.0) | 6/127 (4.7) | 5/107 (4.7) |
| Endocardium | 3/616 (0.5) | 2/489 (0.4) | 1/127 (0.8) | 1/107 (0.9) |
| Medical device | 2/616 (0.3) | 2/489 (0.4) | 0/127 (0.0) | 0/107 (0.0) |
| Others | 15/616 (2.4) | 8/489 (1.6) | 7/127 (5.5) | 7/107 (6.5) |
| Unknown | 23/616 (3.7) | 16/489 (3.3) | 7/127 (5.5) | 7/107 (6.5) |

**Blood purification therapy**

| Any BPT | 127/616 (20.7) | 127/127 (100.0) | 107/107 (100.0) | 82/82 (100.0) |
| Any CRRT | 107/616 (17.4) | 107/127 (84.3) | 107/107 (100.0) | 82/82 (100.0) |
| CRRT for renal indications | 82/613 (13.4) | 82/126 (65.1) | 82/106 (77.4) | 82/82 (100.0) |
| Within 24 h | 68/613 (11.1) | 68/126 (54.0) | 68/106 (64.2) | 68/82 (82.9) |
| Within 24 and 48 h | 7/613 (1.1) | 7/126 (5.6) | 7/106 (6.6) | 7/82 (8.5) |
| After 48 h | 7/613 (1.1) | 7/126 (5.6) | 7/106 (6.6) | 7/82 (8.5) |
| CRRT for non-renal indications | 33/612 (5.4) | 33/127 (26.0) | 33/107 (30.8) | 8/82 (9.8) |
| Within 24 h | 32/612 (5.2) | 32/127 (25.2) | 32/107 (29.9) | 8/82 (9.8) |
| Within 24 and 48 h | 0/612 (0.0) | 0/127 (0.0) | 0/107 (0.0) | 0/82 (0.0) |
Table 5 (continued)

| Variables                                                                 | All (N = 616) | No BPT (N = 489) | Any BPT (N = 127) | Any CRRT (N = 107) | CRRT for non-renal indications (N = 82) | CRRT for renal indications (N = 33) | IRRT (N = 28) | PMX-DHP (N = 42) |
|---------------------------------------------------------------------------|---------------|------------------|-------------------|-------------------|--------------------------------------|-----------------------------------|--------------|------------------|
| After 48 h                                                                 | 1/612 (0.2)   | –                | 1/127 (0.8)       | 1/107 (0.9)       | 0/82 (0.0)                           | 1/33 (3.0)                       | 0/28 (0.0)   | 0/42 (0.0)       |
| IRRT                                                                     | 28/611 (4.6)  | –                | 28/126 (22.2)     | 15/106 (14.2)     | 14/81 (17.3)                        | 4/33 (12.1)                      | 28/28 (100.0)| 6/41 (14.6)      |
| Within 24 h                                                               | 8/611 (1.3)   | –                | 8/126 (6.4)       | 2/106 (1.9)       | 1/81 (1.2)                           | 1/33 (3.0)                       | 8/28 (28.6)  | 3/41 (7.3)       |
| Within 48 h                                                               | 4/611 (0.7)   | –                | 4/126 (3.2)       | 1/106 (0.9)       | 1/81 (1.2)                           | 1/33 (3.0)                       | 4/28 (14.3)  | 1/44 (2.4)       |
| After 48 h                                                                 | 16/611 (2.6)  | –                | 16/126 (12.7)     | 12/106 (11.3)     | 12/81 (14.8)                        | 2/33 (6.1)                       | 16/28 (57.1) | 2/41 (4.9)       |
| PMX-DHP                                                                   | 42/611 (6.9)  | –                | 42/127 (33.1)     | 32/107 (29.9)     | 24/82 (29.3)                        | 11/33 (33.3)                     | 6/28 (21.4)  | 42/42 (100.0)    |
| Within 24 h                                                               | 37/611 (6.1)  | –                | 37/127 (29.1)     | 29/107 (27.1)     | 21/82 (25.6)                        | 11/33 (33.3)                     | 6/28 (21.4)  | 37/42 (88.1)     |
| Within 24 and 48 h                                                       | 4/611 (0.7)   | –                | 4/127 (3.2)       | 2/107 (1.9)       | 2/82 (2.4)                          | 0/33 (0.0)                       | 0/28 (0.0)   | 4/42 (9.5)       |
| After 48 h                                                                 | 1/611 (0.2)   | –                | 1/127 (0.8)       | 1/107 (0.9)       | 0/82 (0.0)                           | 1/33 (3.0)                       | 4/28 (14.3)  | 1/44 (2.4)       |
| Other therapies                                                           |               |                  |                   |                   |                                      |                                  |              |                  |
| Mechanical ventilation within 24 h                                        | 281/612 (54.1)| 190/485 (39.2) | 91/127 (71.7)     | 79/107 (73.8)     | 59/82 (72.0)                        | 28/33 (84.9)                      | 19/28 (67.9) | 31/42 (73.8)     |
| Inotropes or vasopressors                                                 | 312/610 (51.1)| 220/484 (45.5) | 92/126 (73.0)     | 81/106 (76.4)     | 63/81 (77.8)                        | 26/33 (78.8)                      | 17/28 (60.7) | 31/41 (75.6)     |
| Antimicrobial therapy                                                    | 590/596 (99.0)| 471/473 (99.6) | 119/123 (96.8)    | 100/104 (96.2)    | 76/80 (95.0)                        | 31/32 (96.9)                      | 27/27 (100.0)| 41/41 (100.0)    |
| Drainage or operation                                                    | 221/612 (36.1)| 168/486 (34.6) | 53/126 (42.1)     | 47/106 (44.3)     | 32/81 (39.5)                        | 21/33 (63.6)                      | 10/28 (35.7) | 22/42 (52.4)     |

Data are expressed as medians (interquartile ranges) for continuous variables and numbers (%) for categorical variables. Missing data were not included.

**Abbreviations**
- AKI: Acute kidney injury
- BPT: Blood purification therapy
- CRRT: Continuous renal replacement therapy
- IRRT: Intermittent renal replacement therapy
- PMX-DHP: Polymyxin B immobilized fiber column-direct hemoperfusion

**Acknowledgements**
The other Tohoku Sepsis Registry investigators also contributed to the collection and analysis of data at each institution: Tohoku University Hospital, Hachinohe City Hospital, Ohta Nishinouchi Hospital, Osaki Citizen Hospital, Niigata University Medical and Dental Hospital, Sendai City Hospital, South Miyagi Medical Center, Sendai Medical Center, Yamagata Prefectural Central Hospital, and Akita University Hospital. We would like to thank S. Osaki for data management and administrative support.

**Authors’ contributions**
KS designed the study and wrote the initial draft of the manuscript. KN contributed to analysis and interpretation of data and assisted in the preparation of the manuscript. HN contributed to the conception of the study and critically revised the manuscript. All other authors have contributed to data collection and interpretation, and critically reviewed the manuscript. All authors read and approved the final manuscript.

**Funding**
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**
The data that support the findings of this study are available from the principal investigator of the Tohoku Sepsis Registry, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the principal investigator of the Tohoku Sepsis Registry.

**Declarations**

**Ethics approval and consent to participate**
All data were retrieved from a database named Tohoku Sepsis Registry (University Hospital Medical Information Network Clinical Trials Registry No. UMIN000010297). The Institutional Review Board of each institution approved the study. All Institutional Review Boards waived the need for informed consent due to the observational study design requiring no treatments beyond the daily clinical practice, according to the Japanese guideline (Ministry of Education, Culture, Sports, Science and Technology, and Ministry of Health, Labor and Welfare, Japan; Ethical Guidelines for Medical and Health Research Involving Human Subjects. March 2015).

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan. 2Department of Environmental Health Science and Public Health, Akita University Graduate School of Medicine, Akita, Japan. 3Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. 4Department of Emergency and Critical Care Medicine, Tohoku University.
Received: 30 November 2020   Accepted: 29 August 2021
Published online: 08 September 2021

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801.
2. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318:1241.
3. Alboaid R, Basu RK, Goldstein SL, Bagshaw SM. Sepsis-associated acute kidney injury. Semin Nephrol. 2015;35:2–11.
4. Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit Care. 2018;22:262.
5. Monard C, Rimmelé T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif. 2019;47(Suppl 3):1–14.
6. Zhang P, Yang Y, Lv R, Zhang Y, Xie W, Chen J. Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial. Nephrol Dial Transpl. 2012;27:967–73.
7. Albino BB, Balbi AL, Abrião JMG, Ponce D. Dialysis complications in acute kidney injury patients treated with prolonged intermittent renal replacement therapy sessions lasting 10 versus 6 hours: results of a randomized clinical trial. Artif Organs. 2015;39:423–31.
8. Ghanii RA, Zainudin S, Ctkong N, Rahman AFA, Wafa SRWSH, Mohamad M, et al. Serum IL-6 and IL-1ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology. 2006;11:386–93.
9. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Very high volume haemofiltration with the Cascade system in septic shock patients. Intensive Care Med. 2015;41:2111–20.
10. Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVVORE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39:1535–46.
11. Park JT, Lee H, Kre YK, Park S, Oh HJ, Han SH, et al. High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial. Am J Kidney Dis. 2018;68:599–608.
12. Choi AE, Yoon HJ, Lee KY, Sun IO. Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy. Ren Fail. 2018;40:403–9.
13. Liu H, Liu Y, Sun JK, Xu QL, Yan Y, Chen YM, et al. Extravascular lung water monitoring of renal replacement therapy in lung water scavenging for septic acute kidney injury. Int J Clin Exp Med. 2015;8:18907–16.
14. Barbard SD, Clerje-Jehl R, Boudrejdem A, Hennu R, Montin F, Bruyère R, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Med. 2018;379:1431–42.
15. Kobashi S, Maruhashi T, Nakamura T, Hatabayashi E, Kon A. The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center retrospective comparative study. Acute Med Surg. 2019;6:60–7.
16. Pickkers P, Vassiliou T, Ligurs T, Prato F, Tissieres P, Kloess S, et al. Sepsis management with a blood purification membrane: European experience. Blood Purif. 2019;47(Suppl 3):1–9.
17. Schwendinghamer V, Girardot T, Chauvel K, Grégoire A, Monard C, Huriaux L, et al. oXiris® Use in Septic Shock: experience of Two French Centres. Blood Purif. 2019;47(Suppl 3):1–7.
18. Hawchar F, Liszlo I, Oveges N, Trády D, Ondrík Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172–8.